Sumitomo Chemical’s Q2 fiscal 2025 results show notable improvements in core operating income and net profits, driven by strong sales at Sumitomo Pharma and favorable foreign exchange conditions.

• Core operating income surged to JPY 108.7 billion, up JPY 79.2 billion year-over-year, reflecting robust performance in Essential & Green Materials and Sumitomo Pharma.
• Net income attributable to owners of the parent reached JPY 39.7 billion, a substantial increase of JPY 46.2 billion compared to the prior year.
• Sales revenue fell to JPY 1,954 billion, down JPY 146 billion year-on-year, primarily impacted by decreased volumes across most segments.
• Strong performance in Sumitomo Pharma was underscored by sales gains from ORGOVYX and reduced selling expenses.
• The company improved its cash position, with equity rising to JPY 1,179.6 billion but experienced a drop in free cash flow to JPY 41 billion, reflecting increased working capital demands.